1. Committee for Medicinal Products for Human Use (CHMP). 2015 ICH E14 Note for Guidance on: The Clinical Evaluation of QT/QTc Interval Prolongation and Proarrhythmic Potential for Non-antiarrhythmic Drugs (CHMP/ICH/2/04) (ICH E14). European Medicines Agency, London, November 2005. Available at: http://www.ema.europa.eu/docs/en_GB/document_library/Scientific_guideline/2009/09/WC500002879.pdf [Accessed on 15 May 2015]
2. Committee for Medicinal Products for Human Use (CHMP) 2016 ICH Topic E14: The Clinical Evaluation of QT/QTc Interval Prolongation and Proarrhythmic Potential for Non-Antiarrhythmic Drugs Questions and Answers (EMA/CHMP/ICH/310133/2008). European Medicines Agency, London, May 2012. Available at: http://www.ema.europa.eu/docs/en_GB/document_library/Scientific_guideline/2009/09/WC500002878.pdf [Accessed on 15 May 2015]
3. ICH E14 Implementation Working Group 2014 ICH E14 Guideline: The Clinical Evaluation of QT/QTc Interval Prolongation and Proarrhythmic Potential for Non-Antiarrhythmic Drugs. Questions & Answers (R2). International Conference on Harmonisation, Geneva, March 2014. Available at: http://www.ich.org/fileadmin/Public_Web_Site/ICH_Products/Guidelines/Efficacy/E14/E14_QAs_R2_Step4.pdf [Accessed on 15 May 2015]
4. Committee for Medicinal Products for Human Use (CHMP) 2017 Withdrawal Assessment Report for Garenoxacin Masylate (EMEA/H/C/747). (Document Reference EMEA/CHMP/363573/2007). European Medicines Agency, London, October 2007 Available at: http://www.ema.europa.eu/docs/en_GB/document_library/Application_withdrawal_assessment_report/2010/01/WC500067888.pdf [Accessed 26 May 2015]
5. Wang Z, DM G, Krishna G (2007) Retrospective analysis of electrocardiographic changes after administration of oral or intravenous garenoxacin in five phase I, placebo-controlled studies in healthy volunteers. Clin Ther 29:1098–1106